US 12,345,712 B2
Cancer antigen targets and uses thereof
Michel Sadelain, New York, NY (US); and Fabiana Perna, New York, NY (US)
Assigned to MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed by MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed on Nov. 22, 2021, as Appl. No. 17/532,332.
Application 17/532,332 is a division of application No. 15/966,992, filed on Apr. 30, 2018, granted, now 11,193,938.
Application 15/966,992 is a continuation of application No. PCT/US2017/045632, filed on Aug. 4, 2017.
Claims priority of provisional application 62/371,199, filed on Aug. 4, 2016.
Prior Publication US 2022/0074945 A1, Mar. 10, 2022
Int. Cl. A61K 40/31 (2025.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/72 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); G01N 33/566 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); G16B 5/00 (2019.01); G16B 20/00 (2019.01); G16B 20/20 (2019.01); G16B 20/30 (2019.01); G16B 20/50 (2019.01); G16B 30/00 (2019.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01)
CPC G01N 33/57492 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4224 (2025.01); A61K 40/4226 (2025.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01); C07K 14/70575 (2013.01); C07K 14/7158 (2013.01); C07K 14/723 (2013.01); C07K 16/00 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); G01N 33/566 (2013.01); G01N 33/56972 (2013.01); G01N 33/6845 (2013.01); G16B 5/00 (2019.02); G16B 20/00 (2019.02); G16B 20/20 (2019.02); G16B 20/30 (2019.02); G16B 20/50 (2019.02); G16B 30/00 (2019.02); A61K 2039/804 (2018.08); A61K 48/00 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/70 (2013.01); G06F 2218/00 (2023.01)] 18 Claims
 
1. A method for producing an antigen-specific immunoresponsive cell, comprising introducing into an immunoresponsive cell:
(a) a first nucleic acid encoding an antigen recognizing receptor that binds to EMR2, wherein binding of the antigen recognizing receptor to EMR2 is capable of activating the immunoresponsive cell, and
(b) a second nucleic acid encoding a chimeric co-stimulating receptor (CCR) that binds to CLEC12A, wherein binding of the CCR to CLEC12A is capable of stimulating the immunoresponsive cell;
wherein the antigen recognizing receptor binds to EMR2 with a binding affinity that is lower compared to the binding affinity with which the CCR binds to CLEC12A.